Tumor-associated trypsin inhibitor (TATI) is a low molecular weight protein employed as tumor marker. To evaluate the role of the kidney in the clearance of TATI we studied the relationship of serum TATI with the glomerular filtration rate (GFR), and for comparison the relationships of beta 2-microglobulin (beta(2)m) and creatinine with GFR. Urine excretion and renal extraction of TATI were also determined. The decrease in GFR was accompanied by an increase in blood levels of TATI, beta(2)m and creatinine. Serum TATI increased 12.4 times in patients with renal failure (GFR < 20 ml/min) with respect to subjects with normal renal function (P < 0.001, non-parametric Mann-Whitney test), while beta(2)m increased 7.3 times (P < 0.001) and creatinine 4.7 limes (P < 0.001). In patients with GFR 60 to 40 ml/min, only the increase in TATI was statistically significant (P < 0.005). Renal excretion of TATI was low but it increased progressively in renal failure. Renal extraction ranged from 13% to 41%, for a mean 24.87. These results suggest that TATI is handled by the kidney and that it is a sensitive marker of reduction in renal function.
|Autori:||TRAMONTI G; FERDEGHINI M; DONADIO C; ANNICHIARICO C; NORPOTH M; BIANCHI R; BIANCHI C|
|Titolo:||Tumor-associated trypsin inhibitor (TATI) and renal function|
|Anno del prodotto:||1997|
|Appare nelle tipologie:||1.1 Articolo in rivista|